Back to Stocks

ADMA

ADMA BIOLOGICS, INC.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

ADMA Biologics has reached a pivotal operational inflection point, transforming from a capital-intensive growth phase into a high-margin, cash-generative entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline growth in ASCENIV, ADMA's financial health reveals significant vulnerabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ADMA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company in the midst of a high-stakes transition. On one hand, the operational success of ASCENIV and the implementation of the yield-enhancement process provide a clear path toward sustainable profitability and higher margins. The expansion into the pediatric market suggests that the top-line growth trajectory remains intact despite a challenging competitive environment for standard IVIG products. However, the financial trade-off is a stark increase in leverage and a concentrated dependency on a few key customers and suppliers. The decision to prioritize share repurchases via debt during a period of competitive pricing pressure is a bold bet on the stability of the ASCENIV franchise. Investors must now weigh the genuine manufacturing breakthroughs against the risks of a leveraged balance sheet and the volatility of the global plasma supply chain.

Selected Quarter

Core Takeaway

ADMA has successfully pivoted to a high-margin model via yield enhancement, but has traded balance sheet stability for aggressive share repurchases.

Investor Lens

The trade-off between aggressive capital return (buybacks) and the need for a liquidity cushion amid competitive pricing wars.

Watch Next

Quarterly BIVIGAM volume trends and the impact of the pediatric label expansion on ASCENIV revenue.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.45Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%
bullishMay 6

Gross margins increased from 53.2% to 70.5% due to yield enhancement and product mix.

margin expansion
90%
bullishMay 6

Net income rose to $45.3 million compared to $26.9 million in the prior year period.

earnings beat
70%
bullishMay 6

Executed $125 million accelerated share repurchase program.

buyback
60%
bearishMay 6

Significant increase in long-term debt to fund buybacks increases financial risk.

dilution risk
40%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a company in the midst of a high-stakes transition. On one hand, the operational success of ASCENIV and the implementation of the yield-enhancement process provide a clear path toward sustainable profitability and higher margins. The expansion into the pediatric market suggests that the top-line growth trajectory remains intact despite a challenging competitive environment for standard IVIG products. However, the financial trade-off is a stark increase in leverage and a concentrated dependency on a few key customers and suppliers. The decision to prioritize share repurchases via debt during a period of competitive pricing pressure is a bold bet on the stability of the ASCENIV franchise. Investors must now weigh the genuine manufacturing breakthroughs against the risks of a leveraged balance sheet and the volatility of the global plasma supply chain.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.